UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant toTo Section 13 or 15(d) of the Securities Exchange Act of 1934

~~the~~Date ~~Securities~~of ~~Exchange~~Report ~~Act~~(Date of ~~1934~~earliest event reported): February 14, 2014

Date of Report (Date of earliest event reported): February 3, 2014

LVB ACQUISITION, INC.

BIOMET, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Delaware Indiana	000-54505 001-15601	26-0499682 35-1418342
DelawareIndiana	000-54505001-15601	26-049968235-1418342
(State or other jurisdiction of incorporation)	(Commission File Number)	(~~IRS~~I.R.S. Employer Identification No.)

56 East Bell Drive

Warsaw, Indiana 46582

(Address of Principal Executive Offices, Including Zip Code)

(574) 267-6639

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 85.~~01.~~02 ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 314, 2014, ~~the~~Michael ~~Company~~Dal ~~issued~~Bello aresigned ~~press~~from ~~release announcing~~ the ~~settlement~~ ofBoard ~~the Multi-District Litigation entitled MDL 2391 – In Re: Biomet M2A Magnum Hip Implant Product Liability Litigation. As~~ of ~~January 31~~Directors, ~~2014, there were 1012 lawsuits pending in~~ the ~~MDL. Additional~~Audit ~~lawsuits~~Committee ~~filed~~of in the ~~MDL~~ byBoard ~~April 15, 2014 may participate in the settlement. Biomet continues to evaluate the inventory~~ of ~~lawsuits~~Directors ~~in the MDL pursuant to the categories~~ and ~~procedures~~Compensation ~~set~~Committee ~~forth~~of in the ~~settlement~~Board ~~agreement. The final amount~~ of ~~payments~~Directors under the settlement is uncertain. However, the Company believes that the payments under the settlement will exhaust the Company’s self-insured retention under its insurance program, which is $50.0 million, equal to the Company’s current accrual for contingencies for claims associated with metal-on-metal hip products. If this should occur, the Company would have an insurance claim for the amount by which ultimate losses under the settlement exceed the self-insured retention amount. Biomet maintains $100.0 million of ~~third-party~~each ~~insurance coverage. The Company’s insurance carriers have been placed on notice~~ of ~~the~~LVB ~~claims that are subject to the settlement~~Acquisition, ~~and have been placed on notice of the terms of the settlement~~Inc. ~~As is customary in these situations, certain of the Company’s insurance carriers have reserved all rights under their respective policies~~ and ~~could still ultimately deny coverage for some or all of the Company’s insurance claims. However~~Biomet, ~~the Company continues to believe its contracts with the insurance carriers are enforceable for these claims and the settlement agreement~~Inc. ~~Therefore~~(collectively, ~~it believes it is probable that it would receive from its insurance carriers~~ the ~~full amount by which the ultimate losses under the settlement exceed $50~~“Company”).~~0 million~~ Mr. ~~The~~Dal ~~settlement~~Bello ~~does~~did not ~~affect~~resign ~~certain other claims relating to the Company’s metal-on-metal hip products that are pending~~ in ~~various~~connection ~~state courts, and other claims may be filed in the future. The Company’s $50.0 million accrual for contingencies associated~~ with ~~metal-on-metal hip products is unchanged since November 30, 2013. The Company is currently assessing~~ any ~~necessary~~disagreement ~~adjustments~~with to the ~~current~~Company ~~accrual~~or ~~amount to~~its ~~cover the estimated full amount of the settlement, and assessing any potential receivables to be recorded for recoveries from the insurance carriers~~management.

~~The~~Effective ~~court~~on ~~order~~February ~~relating~~14, 2014, the Board of Directors appointed Timur Akazhanov as a director to serve out Mr. Dal Bello’s term. Mr. Akazhanov is an Associate at The Blackstone Group (“Blackstone”), one of the ~~settlement~~four investment firms that collectively and ~~the~~indirectly, ~~press~~through ~~release~~their ~~are~~affiliation ~~filed~~with ~~herewith~~various asprivate ~~exhibit~~equity 10funds, control LVB Acquisition Holding, LLC, which in turn controls the Company.1 Pursuant to the Amended and ~~99.1~~Restated Limited Liability Company Operating Agreement of LVB Acquisition Holding, ~~respectively~~LLC, ~~and~~Blackstone ~~are incorporated~~has the right to nominate two directors to our Board of Directors. Mr. Dal Bello had been previously designated by ~~reference~~Blackstone ~~herein~~to serve on our Board of Directors and Blackstone has notified the Company that it is designating Mr. Akazhanov to fill the vacancy resulting from Mr. Dal Bello’s resignation.

~~Item~~On 9February 14, 2014, J.01 Pat Richardson resigned his position as Vice President and Corporate Controller in order to become the Company’s Vice President, Investor Relations. In connection with this transition, Mr. Richardson resigned from his position as principal accounting officer. Also on February 14, 2014, the Company designated Daniel P. Florin as the Company’s principal accounting officer. Mr. Florin, age 49, has been Senior Vice President and Chief Financial ~~Statements~~Officer of the Company since June 2007. Prior thereto, Mr. Florin served as Vice President and ~~Exhibits~~Corporate Controller for Boston Scientific Corporation since 2001. Prior to being appointed as Corporate Controller in 2001, Mr. Florin served in financial leadership positions within Boston Scientific Corporation and its various business units since July 1995 and was with C. R. Bard from October 1990 through June 1995.

(d) Exhibits.

Exhibit No.		Document
10.1		Court order
99.1		Press Release issued February 3, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned hereunto duly authorized.

Date: February 4 21, 2014

LVB ACQUISITION, INC. /s/ Bradley J. Tandy By: Bradley J. Tandy Its: Senior Vice President, General Counsel and Secretary ~~BIOMET, INC. /s/ Bradley J. Tandy By: Bradley J. Tandy Its: Senior Vice President, General Counsel and Secretary~~




BIOMET, INC.

/s/ Bradley J. Tandy
By:			Bradley J. Tandy
Its:			Senior Vice President, General Counsel and Secretary

Filing Compare · BIOMET INC